BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus
Kirsten Fairfax, Ian R Mackay, Fabienne Mackay
IUBMB Life | WILEY | Published : 2012
In November 2009, Human Genome Sciences and Glaxo-Smith Kline [HGS (Rockville, Maryland) and GSK, respectively] announced that Belimumab, a neutralizing antibody to the tumour necrosis factor (TNF)-like ligand, B-cell activating factor (BAFF belonging to the TNF family, also named BLyS), met the primary endpoints in two phase III clinical trials in systemic lupus erythematosus (SLE, lupus). In March 2011, Belimumab was approved by the US Federal Drug Agency for treatment of SLE patients; this was followed in May with approval by the European Medicines Agency for use in the European Union. This is an exciting development as it is the first successful late-stage clinical trial in SLE in over 4..View full abstract
Kirsten Fairfax and Fabienne Mackay are supported by the Australian National Health and Medical Research Council (NHMRC). Ian Mackay is supported by the Australian Research Council (ARC). Thank you to Dr. Louise Fairfax for proofreading this manuscript.